8-K: Vivani Medical Expands Board with Appointment of Industry Veteran Daniel Bradbury

Vivani Medical appoints Daniel Bradbury, former CEO of Amylin Pharmaceuticals, to its Board of Directors as they focus on developing GLP-1 implants.

Summary

• Vivani Medical has appointed Daniel Bradbury to its Board of Directors, effective March 4, 2024.
• Mr. Bradbury fills a newly created vacancy, expanding the board from five to six members.
• He will also serve on the Audit Committee.
• Mr. Bradbury brings extensive experience, including his role as CEO of Amylin Pharmaceuticals, which developed the first once-weekly GLP-1 receptor agonist.
• Vivani is focused on developing miniature, long-term GLP-1 implants for obesity and type 2 diabetes.
• Mr. Bradbury will receive an annual cash retainer of $35,000 for board service and $10,000 for Audit Committee service.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced industry leader like Daniel Bradbury is a very positive development for Vivani, suggesting strong potential for future growth and success. The focus on GLP-1 implants is also a promising area.

Positives

• The appointment of Daniel Bradbury brings significant industry expertise to Vivani's board.
• Mr. Bradbury's experience with GLP-1 drugs aligns well with Vivani's focus on developing GLP-1 implants.
• His leadership experience at Amylin, including its acquisition for $7.1 billion, is a strong asset.
• The expansion of the board suggests a commitment to growth and strategic oversight.
• Mr. Bradbury's prior advisory role with Vivani indicates a pre-existing understanding of the company.

Risks

• The company is still in the preclinical stage, and the development of their implants is subject to regulatory and clinical trial risks.
• The company has a history of losses and may need to raise additional capital.
• There are risks related to the development and commercialization of their products, including NPM-115 and NPM-119.
• There are potential delays in submitting and receiving regulatory clearance or approval to conduct development activities.
• The company faces risks related to the initiation, enrollment and conduct of planned clinical trials and the results therefrom.

Future Outlook

Vivani is focused on developing miniature, long-term GLP-1 implants for the treatment of obesity, type 2 diabetes, and potentially other chronic diseases. They are also assessing strategic options for their neurostimulation technology.

Management Comments

• Adam Mendelsohn, Ph.D., Vivani President and Chief Executive Officer, stated that Dan's guidance has been invaluable since 2017.
• Adam Mendelsohn also said that Dan's leadership expertise and experience developing and commercializing the world's first GLP-1 drug will be pivotal as they focus on delivering miniature, long-term GLP-1 implants.

Industry Context

The appointment of Daniel Bradbury, with his extensive experience in GLP-1 drug development, highlights Vivani's commitment to the growing market for obesity and diabetes treatments. The GLP-1 market is currently dominated by blockbuster drugs like Ozempic, Trulicity, and Wegovy, and Vivani is aiming to compete with a novel implantable delivery system.

Comparison to Industry Standards

• Daniel Bradbury's previous role as CEO of Amylin Pharmaceuticals, which developed Bydureon, a once-weekly GLP-1 agonist, provides a direct comparison to the current market leaders like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Trulicity).
• Vivani's approach of using implantable drug delivery systems is a departure from the standard injectable or oral medications, potentially offering a competitive advantage in terms of patient adherence.
• The $7.1 billion acquisition of Amylin by Bristol-Myers Squibb demonstrates the significant value that can be created in the GLP-1 market, setting a high benchmark for Vivani's potential.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Daniel Bradbury positively, potentially increasing investor confidence.
• Employees may be motivated by the addition of an experienced leader to the board.
• Customers (potential patients) may benefit from the development of new and improved treatment options for obesity and type 2 diabetes.
• Suppliers and creditors may see the company as a more stable and reliable partner due to the board's enhanced expertise.

Next Steps

• Vivani will continue to develop its GLP-1 implants, NPM-115 and NPM-119.
• The company will focus on the LIBERATE-1 trial and reporting of trial results.
• Vivani will continue to assess strategic options for advancing Cortigent's technology.

Key Dates

Keywords

GLP-1 implants, Board of Directors, Daniel Bradbury, Vivani Medical, biopharmaceutical, obesity, type 2 diabetes, Amylin Pharmaceuticals, drug development, Audit Committee